A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma.
- SM Goldinger (Autor*in)
- S Gobbi (Autor*in)
- M Ding (Autor*in)
- AL Frauchiger (Autor*in)
- Fink-Puches, R. (Autor*in)
- CD Klemke (Autor*in)
- B Dreno (Autor*in)
- M Bagot (Autor*in)
- C Assaf (Autor*in)
- R Dummer (Autor*in)
Aktivität: Vortrag oder Poster › Poster